Literature DB >> 6402089

HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis.

M J Garlepp, R L Dawkins, F T Christiansen.   

Abstract

Antibodies to the acetylcholine receptor and HLA antigens have been studied in patients with myasthenia gravis occurring in association with penicillamine treatment. The properties of the antiacetylcholine receptor in these patients differed from those in patients with idiopathic myasthenia gravis in terms of specificity and affinity. These patients had an increased prevalence of HLA Bw35 and DR1 compared to controls and a decreased frequency of B8 and DR3 compared to patients with idiopathic myasthenia gravis. Likewise, they had a decreased frequency of DR4 compared to patients with rheumatoid arthritis. These data provide supportive evidence for a role for penicillamine in the induction of myasthenia gravis in genetically predisposed individuals.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402089      PMCID: PMC1546897          DOI: 10.1136/bmj.286.6362.338

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  15 in total

1.  Genetic control of suppressor lymphocyte function in myasthenia gravis: relationship of impaired suppressor function to HLA-B8/DRW3 and cold reactive lymphocytotoxic antibodies.

Authors:  P J Zilko; R L Dawkins; K Holmes; C Witt
Journal:  Clin Immunol Immunopathol       Date:  1979-10

2.  Penicillamine-associated myasthenia gravis, antiacetylcholine receptor and antistriational antibodies.

Authors:  C L Masters; R L Dawkins; P J Zilko; J A Simpson; R J Leedman
Journal:  Am J Med       Date:  1977-11       Impact factor: 4.965

3.  HLA antigens in pencillamine-induced myasthenia gravis.

Authors:  J Keesey; S Novom
Journal:  Neurology       Date:  1979-04       Impact factor: 9.910

4.  Penicillamine-induced myasthenia gravis in progressive systemic sclerosis.

Authors:  C F Torres; R C Griggs; J Baum; A S Penn
Journal:  Arthritis Rheum       Date:  1980-04

5.  Cross-reactivity of anti-acetylcholine receptor autoantibodies.

Authors:  M J Garlepp; P H Kay; R L Dawkins; R C Bucknall; A Kemp
Journal:  Muscle Nerve       Date:  1981 Jul-Aug       Impact factor: 3.217

6.  Penicillamine-associated myasthenia gravis.

Authors:  J W Albers; R J Hodach; D W Kimmel; W L Treacy
Journal:  Neurology       Date:  1980-11       Impact factor: 9.910

7.  DR antigens and rheumatoid arthritis: a study of two populations.

Authors:  J C Woodrow; F E Nichol; G Zaphiropoulos
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-14

Review 8.  Myasthenia gravis and D-penicillamine.

Authors:  R L Dawkins; M J Garlepp; B L McDonald; J Williamson; P J Zilko; J Carrano
Journal:  J Rheumatol Suppl       Date:  1981 Jan-Feb

9.  Penicillamine-induced myasthenia gravis associated with antibodies to acetylcholine receptor.

Authors:  A S Russell; J M Lindstrom
Journal:  Neurology       Date:  1978-08       Impact factor: 9.910

10.  Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility.

Authors:  J R Batchelor; K I Welsh; R M Tinoco; C T Dollery; G R Hughes; R Bernstein; P Ryan; P F Naish; G M Aber; R F Bing; G I Russell
Journal:  Lancet       Date:  1980-05-24       Impact factor: 79.321

View more
  14 in total

1.  Immunogenetic markers in rheumatic diseases.

Authors:  L Martin; M J Fritzler
Journal:  Can Fam Physician       Date:  1990-03       Impact factor: 3.275

2.  Repertoires of autoantibodies against homologous eye muscle in ocular and generalized myasthenia gravis differ.

Authors:  C W Zimmermann; F Eblen
Journal:  Clin Investig       Date:  1993-06

3.  HLA associations with inclusion body myositis.

Authors:  M J Garlepp; B Laing; P J Zilko; W Ollier; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

4.  Myasthenic pseudo-internuclear ophthalmoplegia due to penicillamine.

Authors:  J George; E G Spokes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-09       Impact factor: 10.154

Review 5.  New treatment approaches to myasthenia gravis.

Authors:  C W Havard; V Fonseca
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 6.  New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity.

Authors:  Aaron W Michels; David A Ostrov
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

7.  D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence?

Authors:  A P Andonopoulos; E Terzis; E Tsibri; C A Papasteriades; T Papapetropoulos
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

Review 8.  Penicillamine in rheumatoid arthritis. A problem of toxicity.

Authors:  H G Taylor; A Samanta
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

9.  Myasthenia gravis. Pathogenesis and current concepts in management.

Authors:  C W Havard; G K Scadding
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

10.  Reduced sulphoxidation capacity in D-penicillamine induced myasthenia gravis.

Authors:  P Seideman; R Ayesh
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.